SYSatoshi Yamanaka

Satoshi Yamanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Satoshi Yamanaka has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Market Analysis of Biological Control Agents in Japan: Current Trends and Future Perspectives

    by Norihide Hinomoto, Satoshi Yamanaka

    The objective of this study is to provide a comprehensive analysis of the market structure and utilization trends of biological control agents (BCAs) in Japan. In light of the MIDORI Strategy for Sustainable Food Systems, which aims to reduce reliance on chemical pesticides, this research clarifies the current standing and role of BCAs— with a specific focus on predatory mites—within the Japanese agricultural landscape using both quantitative and qualitative data. We extracted and analyzed sales statistics and registration data for BCAs in Japan from 1995 to 2023. Our analysis reveals a rapid increase in demand for agents centered on predatory mites, with a significant rise in adoption rates within greenhouse horticulture (e.g., strawberries, eggplants). In particular, sales values have surged for Phytoseiulus persimilis and Neoseiulus californicus as key solutions for spider mite control, alongside Amblyseius swirskii for managing thrips and whiteflies. Although still in the early stages, the Japanese market is showing signs of moving beyond the mere substitution of chemical pesticides, beginning to shift towards embedding these agents into the entire cultivation system. The introduction of phytoseiid BCAs has significantly contributed to the reduction of chemical pesticide use in Japanese horticulture, and they are expected to play an even more vital role in its sustainable future. To sustain these activities, we recommend to the government that the registration of biological control agents (BCAs) be further simplified than it is now Acknowledgements: This work was partly supported by Cabinet Office, Government of Japan, Moonshot Research and Development Program for Agriculture, Forestry and Fisheries (funding agency: Bio-oriented Technology Research Advancement Institution) JPJ009237.

  • Open Access

    In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID

    by Kohdai Yamada, Satoshi Yamanaka, Hiroyuki Yamakoshi, Aki Kohyama, Yoshiharu Iwabuchi, Hidetaka Kosako, Tatsuya Sawasaki

    Heterobifunctional molecules, such as proteolysis-targeting and autophagy-targeting chimera, represent new drug concepts. They are composed of two protein binders that can induce proximity interactions between two proteins and protein catalysis. Currently, cereblon (CRBN)- and von Hippel-Lindau (VHL)-binders with thalidomide- and VH032-backbones are widely used as E3 ligase binders. Here, we developed a method to validate proteins that interact with heterobifunctional molecules in cells using AirID, a proximity biotinylation enzyme. Interactome of target proteins was validated for six heterobifunctional molecules. ThBD-AirID, a fusion of the thalidomide-binding domain (ThBD) of CRBN and AirID, effectively biotinylated the target proteins. AirID fused to full-length VHL also exhibited highly effective biotinylation. Heterobifunctional molecules with the same target binder but different E3 binders showed different proximity interactome profiles in cells. Analysis using ThBD-AirID revealed a nuclear interaction between androgen receptor and ARV-110. AirID-fused ThBD and VHL could be useful for validating the heterobifunctional molecular interactome in cells.


  • Open Access

    In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID

    by Kohdai Yamada, Satoshi Yamanaka, Hiroyuki Yamakoshi, Aki Kohyama, Yoshiharu Iwabuchi, Hidetaka Kosako, Tatsuya Sawasaki

    Heterobifunctional molecules, such as proteolysis-targeting and autophagy-targeting chimera, represent new drug concepts. They are composed of two protein binders that can induce proximity interactions between two proteins and protein catalysis. Currently, cereblon (CRBN)- and von Hippel-Lindau (VHL)-binders with thalidomide- and VH032-backbones are widely used as E3 ligase binders. Here we developed a method to validate proteins that interact with heterobifunctional molecules in cells using AirID, a proximity biotinylation enzyme. Interactome of target proteins was validated for six heterobifunctional molecules. ThBD-AirID, a fusion of the thalidomide-binding domain (ThBD) of CRBN and AirID, effectively biotinylated the target proteins. AirID fused to full-length VHL also exhibited highly effective biotinylation. Heterobifunctional molecules with the same target binder but different E3 binders showed different proximity interactome profiles in cells. Analysis using ThBD-AirID revealed a nuclear interaction between androgen receptor and ARV-110. AirID-fused ThBD and VHL could be useful for validating the heterobifunctional molecular interactome in cells.

  • Open Access

    Cell-type specific, inducible and acute degradation of targeted protein in mice by two degron systems

    by Motoi Yamashita, Chihiro Ogawa, Baihao Zhang, Tetsuro Kobayashi, Aneela Nomura, Clive Barker, Chengcheng Zou, Satoshi Yamanaka, Ken-Ichiro Hayashi, Yoichi Shinkai, et al.

    Despite its broad application in in vitro studies, the application of targeted protein degradation (TPD) to animal models faces considerable challenges. Here, we develop inducible and cell-type specific TPD systems in mice using two degron systems: Oryza sativa TIR1F74G (OsTIR1)-auxin-inducible degron 2 (AID2) and human cereblon (hCRBN)-SALL4 degron (S4D). Efficient degradation of Satb1Venus protein by these systems recapitulates phenotypes observed in the Satb1-deficient mice. These TPD are successfully applied in both the fetal and neonatal stages. The OsTIR1-AID2 system proves to be effective for membrane proteins such as PD-1, emulating the effects of the anti-PD-1 antibody. Degradation of Bcl11b reveals a role of Bcl11b which was not characterized by the Cre-loxP system. Collectively, in vivo TPD technologies developed in this study enable inducible, temporal, and cell type-specific depletion of target proteins with high efficacy in mice. These technologies have a wide range of applications in the diverse fields of biological and medical research.


  • Top Cited Papers
    Open Access

    Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

    by Satoshi Yamanaka, Hirotake Furihata, Yuta Yanagihara, Akihito Taya, Takato Nagasaka, Mai Usui, Koya Nagaoka, Yuki Shoya, Kohei Nishino, Shuhei Yoshida, et al.

    Lenalidomide, an immunomodulatory drug (IMiD), is commonly used as a first-line therapy in many haematological cancers, such as multiple myeloma (MM) and 5q myelodysplastic syndromes (5q MDS), and it functions as a molecular glue for the protein degradation of neosubstrates by CRL4CRBN. Proteolysis-targeting chimeras (PROTACs) using IMiDs with a target protein binder also induce the degradation of target proteins. The targeted protein degradation (TPD) of neosubstrates is crucial for IMiD therapy. However, current IMiDs and IMiD-based PROTACs also break down neosubstrates involved in embryonic development and disease progression. Here, we show that 6-position modifications of lenalidomide are essential for controlling neosubstrate selectivity; 6-fluoro lenalidomide induced the selective degradation of IKZF1, IKZF3, and CK1α, which are involved in anti-haematological cancer activity, and showed stronger anti-proliferative effects on MM and 5q MDS cell lines than lenalidomide. PROTACs using these lenalidomide derivatives for BET proteins induce the selective degradation of BET proteins with the same neosubstrate selectivity. PROTACs also exert anti-proliferative effects in all examined cell lines. Thus, 6-position-modified lenalidomide is a key molecule for selective TPD using thalidomide derivatives and PROTACs.


  • Open Access

    Lenalidomide Derivative and PROTAC for Controlling Neosubstrate Degradation

    by Tatsuya Sawasaki, Satoshi Yamanaka, Hirotake Furihata, Yuuki Imai, Yuta Yanagihara, Koya Nagaoka, Yuki Shoya, Shuhei Yoshida, Norio Shibata, Akihito Taya, et al.

    Lenalidomide, an immunomodulatory drug (IMiD), is commonly used as first-line therapy in many haematological cancer diseases, such as multiple myeloma (MM) and 5q myelodysplastic syndromes (5q MDS), and it functions as a molecular glue for the protein degradation of neosubstrates by CRL4CRBN 1–4. Proteolysis-targeting chimeras (PROTACs) using IMiDs with a target protein binder also induce the degradation of target proteins5,6. The targeted protein degradation (TPD) of neosubstrates is crucial for IMiD therapy2–4,7. However, current IMiDs and IMiD-based PROTACs also unexpectedly break down neosubstrates involved in embryonic development and disease progression2–4,8–10. Here, we showed that 6-position modifications of lenalidomide are essential for controlling neosubstrate selectivity; 6-fluoro lenalidomide induced the selective degradation of IKZF1, IZKF3, and CK1α, which are involved in anti-haematological cancer activity2–4, and showed stronger antiproliferative effects on MM and 5q MDS cell lines than lenalidomide. PROTACs using the new lenalidomide derivatives for BET proteins induced the selective degradation of BET proteins with the same neosubstrate selectivity. PROTACs also exerted antiproliferative effects in all cell lines examined, including MM and neuroblastoma cell lines. Thus, 6-position-modified lenalidomide is a key strategy for selective TPD using thalidomide derivatives and PROTACs.

  • Open Access

    A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues

    by Satoshi Yamanaka, Yuto Horiuchi, Saya Matsuoka, Kohki Kido, Kohei Nishino, Mayaka Maeno, Norio Shibata, Hidetaka Kosako, Tatsuya Sawasaki

    Proteolysis-targeting chimaeras (PROTACs) as well as molecular glues such as immunomodulatory drugs (IMiDs) and indisulam are drugs that induce interactions between substrate proteins and an E3 ubiquitin ligases for targeted protein degradation. Here, we develop a workflow based on proximity-dependent biotinylation by AirID to identify drug-induced neo-substrates of the E3 ligase cereblon (CRBN). Using AirID-CRBN, we detect IMiD-dependent biotinylation of CRBN neo-substrates in vitro and identify biotinylated peptides of well-known neo-substrates by mass spectrometry with high specificity and selectivity. Additional analyses reveal ZMYM2 and ZMYM2-FGFR1 fusion protein—responsible for the 8p11 syndrome involved in acute myeloid leukaemia—as CRBN neo-substrates. Furthermore, AirID-DCAF15 and AirID-CRBN biotinylate neo-substrates targeted by indisulam and PROTACs, respectively, suggesting that this approach has the potential to serve as a general strategy for characterizing drug-inducible protein–protein interactions in cells.


  • Open Access

    Thalidomide and its metabolite 5‐hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF

    by Satoshi Yamanaka, Hidetaka Murai, Daisuke Saito, Gembu Abe, Etsuko Tokunaga, Takahiro Iwasaki, Hirotaka Takahashi, Hiroyuki Takeda, Takayuki Suzuki, Norio Shibata, et al.

    EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.


  • Open Access

    An IMiD-induced SALL4 degron system for selective degradation of target proteins

    by Satoshi Yamanaka, Yuki Shoya, Saya Matsuoka, Hisayo Nishida-Fukuda, Norio Shibata, Tatsuya Sawasaki

    Regulating the amount of proteins in living cells is a powerful approach for understanding the functions of the proteins. Immunomodulatory drugs (IMiDs) induce the degradation of neosubstrates by interacting with celebron (CRBN) in the cullin E3 ubiquitin ligase complex (CRL4CRBN). Here, we developed the IMiD-dependent Sal-like protein 4 (SALL4) degron (S4D) system for chemical protein knockdown. In transient assays, an N- or C-terminal S4D tag induced the degradation of proteins localized to various subcellular compartments, including the plasma membrane. The activity of luciferase-S4D was reduced by 90% within 3 h of IMiD treatment. IMiD treatment reduced the expression of endogenous S4D-fused RelA and IκBα in knock-in (KI) experiments. Interestingly, the IκBα knockdown suggested that there may be another, unknown mechanism for RelA translocation to the nucleus. Furthermore, 5-hydroxythalidomide as a thalidomide metabolite specifically degradated S4D-tagged protein. These results indicate that the S4D system is a useful tool for cellular biology.


  • Open Access

    Structural bases of IMiD selectivity that emerges by 5-hydroxythalidomide

    by Hirotake Furihata, Satoshi Yamanaka, Toshiaki Honda, Yumiko Miyauchi, Atsuko Asano, Norio Shibata, Masaru Tanokura, Tatsuya Sawasaki, Takuya Miyakawa

    Thalidomide and its derivatives exert not only therapeutic effects as immunomodulatory drugs (IMiDs) but also adverse effects such as teratogenicity, which are due in part to different C2H2 zinc-finger (ZF) transcription factors, IKZF1 (or IKZF3) and SALL4, respectively. Here, we report the structural bases for the SALL4-specific proteasomal degradation induced by 5-hydroxythalidomide, a primary thalidomide metabolite generated by the enzymatic activity of cytochrome P450 isozymes, through the interaction with cereblon (CRBN). The crystal structure of the metabolite-mediated human SALL4-CRBN complex and mutagenesis studies elucidate the complex formation enhanced by the interaction between CRBN and an additional hydroxy group of (S)-5-hydroxythalidomide and the variation in the second residue of β-hairpin structure that underlies the C2H2 ZF-type neo-morphic substrate (neosubstrate) selectivity of 5-hydroxythalidomide. These findings deepen our understanding of the pharmaceutical action of IMiDs and provide structural evidence that the glue-type E3 ligase modulators cause altered neosubstrate specificities through their metabolism.